<DOC>
	<DOCNO>NCT00021398</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may shrink tumor remove surgery . PURPOSE : Phase II trial study effectiveness radiation therapy chemotherapy follow surgery combination chemotherapy treat patient stage II stage III rectal cancer .</brief_summary>
	<brief_title>Radiation Therapy Chemotherapy Followed Surgery Combination Chemotherapy Treating Patients With Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine local recurrence rate , disease-free survival , overall survival patient stage II III rectal cancer treat neoadjuvant radiotherapy fluorouracil follow surgical resection adjuvant fluorouracil leucovorin calcium . II . Determine toxicity rate patient treat regimen . III . Correlate failure-free survival ultrasound-determined preoperative staging patient treat regimen . IV . Determine quality life patient treat regimen . V. Determine toxicity due treatment , daily stool frequency , sexual dysfunction , disease-free survival correlate quality life parameter patient treat regimen . VI . Correlate clinical selection criterion ability perform sphincter-sparing surgery patient treat regimen . VII . Determine post-chemoradiotherapy pathological response , margin status , lymph node status correlate factor initial clinico-pathologic finding patient treat regimen . OUTLINE : Patients undergo pelvic radiotherapy daily five day week 5 week follow boost radiotherapy twice daily 7 day . Patients also receive neoadjuvant fluorouracil IV continuously day 1-4 36-40 . Patients undergo surgical resection 4-6 week completion radiotherapy . At 4 week surgery , patient receive adjuvant leucovorin calcium IV fluorouracil IV daily five day week . Treatment continue every 4 week 4 course absence disease progression unacceptable toxicity . Quality life assess baseline , completion pelvic boost radiotherapy , 4 week completion chemoradiotherapy ( prior surgery ) , 3 , 6 , 12 month completion study therapy . Patients follow every 3 month 2 year , every 4 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 23-41 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma rectum Tumor extend bowel wall ( T3 ) OR Fixation surround structure ( T4 ) OR Nodal involvement endorectal ultrasound ( N12 ) Tumor extend bowel wall , fix ( T3 ) must : At least 4 cm least 40 % bowel circumference OR Accompanied nodal involvement Evidence transmural penetration confirm 2 following : CT scan Pelvic MRI Transrectal ultrasound Physical exam Proximal extent tumor must extend high 12 cm dentate line must pelvic peritoneal reflexion sacral promontory Regional lymph node involvement allow No distant metastasis CT scan abdomen pelvis chest xray PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 01 Life expectancy : At least 2 year Hematopoietic : Leukocyte count great 4,000/mm3 Platelet count least 100,000/mm3 Hemoglobin great 10 g/dL Hepatic : SGOT SGPT less 1.5 time normal Bilirubin le 1.5 mg/dL Renal : Creatinine le 1.8 mg/dL Other : Not pregnant nursing Negative pregnancy test No prior concurrent malignancy within past 5 year except inactive nonmelanoma skin cancer carcinoma situ cervix No psychiatric condition would preclude informed consent No serious medical illness would limit survival PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy rectal cancer Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy rectal cancer Surgery : No prior surgery rectal cancer , except diagnostic biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>